Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29303425 | 1.00 | NOS1 (0.34) | NOS1AXLNPC1RAB9AHDAC8 | |
| SCHEMBL30975428 | 0.82 | EZH2 (0.39) | NOS1AXLNPC1RAB9AHDAC8 | |
| SCHEMBL29303420 | 0.82 | EZH2 (0.39) | NOS1AXLNPC1RAB9AHDAC8 | |
| SCHEMBL31692187 | 0.77 | — | — | |
| SCHEMBL29303183 | 0.76 | GABRA1 (0.34) | — | |
| SCHEMBL26920959 | 0.76 | GCGR (0.30) | — | |
| SCHEMBL28776591 | 0.76 | NPC1 (0.40) | NPC1RAB9AHDAC8GRM2 | |
| SCHEMBL28776592 | 0.76 | NPC1 (0.35) | NOS1AXLNPC1RAB9AHDAC8 | |
| SCHEMBL1900443 | 0.72 | CCR4 (0.40) | NOS1AXLNPC1RAB9AGRM2 | |
| SCHEMBL18993241 | 0.72 | NOS1 (0.37) | NOS1AXLNPC1RAB9AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM2 | NOS1 2108/4885AXL 2103/4885NPC1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.